Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study
Authors:
Open Access
- 13 December 2019
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 21 (1) , 1-8
Abstract
Background: Systemic sclerosis is a systemic connective tissue disease characterized by endothelium damage, fibrosis, and subsequent atrophy of the skin. Perioral fibrosis produces a characteristic microstomia together with microcheilia, both of which cause severe difficulties and affects patients’ daily life, such as eating and oral hygiene. Since there are no effective and specific therapies, we have aimed at evaluating the response to filler injections of hyaluronic acid together with platelet-rich plasma.Methods: Ten female patients aged between 18 and 70 were included in this study. Each patient was treated with three filler injections of hyaluronic acid and platelet-rich plasma at an interval of 15 to 20 days. Follow-up check-ups were recorded 1, 3, and 24 months after the end of the treatment. During the therapy and the subsequent follow-up, we evaluated the mouth’s opening, freedom of movement of the lips, and skin elasticity.Results: After the treatment, patients had achieved good results already after the first injection and the improvement was maintained in the following months, up to 2 years. In particular, 8 (80%) patients showed a greater mouth’s opening and increased upper lip’s thickness during 1-month follow-up and maintained these results after 2 years (maximum mouth’s opening T0 47.61; T3 49.23; T4 48.60p < 0.0001. Upper lip’s thickness T0 4.20; T3 4.75; T4 4.45p < 0.0001). Moreover, distance between upper and lower incisors (T0 27.05; T3 29.03; T4 28.14p < 0.0001), inter-commissural distance (T0 49.12; T3 51.44; T4 50.31:p < 0.0001), and lower lip’s thickness (T0 3.80; T3 4.85, 5.10; T4 4.25;p < 0.0001) were increased in all of patients in 1-month follow-up, keeping these benefits after 24 months and having a significant increase of skin elasticity 1 month after the end of therapy.Conclusions: Our study demonstrates that filler injections of hyaluronic acid and platelet-rich plasma represent an efficient local therapeutic alternative for patients affected by scleroderma. The treatment has significantly improved patients’ quality of living.Keywords
This publication has 43 references indexed in Scilit:
- Subcutaneous Injections of Platelet-Rich Plasma into Skin Flaps Modulate Proangiogenic Gene Expression and Improve Survival RatesPlastic and Reconstructive Surgery, 2012
- Angiogenic cytokines and growth factors in systemic sclerosisAutoimmunity Reviews, 2011
- Linear Morphea-Induced Atrophy Treated with Hyaluronic Acid Filler InjectionsDermatologic Surgery, 2011
- Can Platelet-rich Plasma Be Used for Skin Rejuvenation? Evaluation of Effects of Platelet-rich Plasma on Human Dermal FibroblastAnnals of Dermatology, 2011
- Experimental study of tendon healing early phase: Is IGF-1 expression influenced by platelet rich plasma gel?Orthopaedics & Traumatology: Surgery & Research, 2010
- Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosisRheumatology, 2008
- A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized sclerodermaJournal of the American Academy of Dermatology, 2006
- Suggested mechanisms of action of UVA phototherapy in morphea: a molecular studyPhotodermatology, Photoimmunology & Photomedicine, 2004
- Treatment of Linear Scleroderma with Oral 1,25‐Dihydroxyvitamin D3 (Calcitriol) in Seven ChildrenPediatric Dermatology, 1999
- Localized scleroderma-response to 1,25-dihydroxyvitamin D3Clinical and Experimental Dermatology, 1990